Assessment of direct biomarkers of aspirin action to develop a precision chemoprevention therapy of colorectal cancer

Ángel Lanas Arbeloa-Instituto de Investigación Sanitaria Aragón0 个研究点目标入组 60 人开始时间: 2018年7月17日最近更新: 2019年1月7日

适应症

试验速览

暂无简介。

•- Age from 18 to 80 years old
•- Recent diagnosis (less than 48h) of colorectal cancer by endoscopy and confirmed by anatomopathological study
•- normal hematologic, biochemical, and coagulation values
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 50

•- Allergy to AAS or to any other NSAID.
•- Rectal cancer requiring neoadjuvant treatment wthin the two weeks following the beginning of ASA treatment.
•- Previous use of AAS, NSAIDs, antiplatelet agents, corticosteroids or misoprostol within the 15 days prior to diagnosis and/or anticipation of need for treatment with any of these drugs during the study period.
•History of peptic ulcer disease or active peptic ulcer or any other GI disease that may be considered a contraindication to the use of ASA, without the concomitant use of proton pump inhibitors.
•- Diagnosis of bleeding disorders.
•- Diagnosis of cancer (excluding non-melanoma skin cancer) during the previous 3 years.
•- Conditions supposing serious comorbidity, excluding diabetes, and including respiratory, cardiac, hepatic and renal diseases.
•- Active smoking.
•- Pregnancy or breastfeeding.
•- History of drug or alcohol abuse.

发起方

Ángel Lanas Arbeloa-Instituto de Investigación Sanitaria Aragón